F. G. Njoroge

发表

Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.

M. McCoy, M. Senior, D. Wyss, 2004, Journal of medicinal chemistry.

A continuous spectrophotometric assay for the hepatitis C virus serine protease.

W. Windsor, B. Malcolm, B. Beyer, 1999, Analytical biochemistry.

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

N. Butkiewicz, F. Gheyas, X. Tong, 2006, Antimicrobial Agents and Chemotherapy.

Novel tricyclic aminoacetyl and sulfonamide inhibitors of Ras farnesyl protein transferase

W. R. Bishop, R. Doll, F. G. Njoroge, 1996 .

Enantioselective Synthesis of 3,3-Difluoropyrrolidin-4-ol, a Valuable Building Block in Medicinal Chemistry.

F. G. Njoroge, H. G. Vandeveer, A. Torrado, 2016, The Journal of organic chemistry.

The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.

F. G. Njoroge, Kevin X. Chen, 2010, Progress in medicinal chemistry.

In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.

V. Pazienza, K. Abid, F. Negro, 2006, The Journal of antimicrobial chemotherapy.

In vitro antiviral activity of SCH 446211 ( SCH 6 ) , a novel inhibitor of the hepatitis C virus NS 3 serine protease

V. Pazienza, K. Abid, F. Negro, 2006 .

5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d).

J. Fox, W. Bode, E. Meyer, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma.

Walter A. Korfmacher, R. Morrison, F. G. Njoroge, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Aging of proteins: immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo.

V. Monnier, R. Nagaraj, F. Hayase, 1989, The Journal of biological chemistry.

Regioselective cobalt-catalyzed addition of sulfides to unactivated alkenes.

F. G. Njoroge, Vinay M Girijavallabhan, C. Alvarez, 2011, The Journal of organic chemistry.

Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.

R. Morrison, F. G. Njoroge, K. Cheng, 2008, Biochemical pharmacology.

Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.

Z. Gu, A. Nomeir, F. Lahser, 2016, Bioorganic & medicinal chemistry letters.

Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.

Z. Gu, C. Espiritu, H. Ren, 2013, Bioorganic & Medicinal Chemistry Letters.

Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.

B. Feld, J. Duca, F. G. Njoroge, 2012, Journal of medicinal chemistry.

A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors.

B. Feld, J. Duca, F. G. Njoroge, 2012, Journal of medicinal chemistry.

Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.

X. Tong, R. Doll, Zhuyan Guo, 2010, Bioorganic & medicinal chemistry letters.

Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors

F. G. Njoroge, Weing Yang, N. Shih, 2010 .

Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.

X. Tong, F. G. Njoroge, K. Cheng, 2009, Bioorganic & medicinal chemistry letters.

Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.

F. G. Njoroge, K. Cheng, J. Pichardo, 2008, Bioorganic & medicinal chemistry.

Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.

A. Arasappan, F. G. Njoroge, W. Pan, 2008, Bioorganic & medicinal chemistry letters.

The chemistry of the Maillard reaction under physiological conditions: a review.

V. Monnier, F. G. Njoroge, F. Njoroge, 1989, Progress in clinical and biological research.

Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Can

Brandon J. Margolis, S. Atwell, Matthew R. Lee, 2017, Journal of Medicinal Chemistry.

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

X. Tong, R. Ralston, Zhuyan Guo, 2008, Antiviral research.

The role of P-glycoprotein in the pharmacokinetics and tissue distribution of a hepatitis C virus protease inhibitor.

F. G. Njoroge, Tongtong Liu, A. Uss, 2009, Drug metabolism letters.

Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.

W. R. Bishop, M. Snow, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity.

V. Madison, F. G. Njoroge, A. Prongay, 2005, Angewandte Chemie.

Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions.

V. Monnier, L. Sayre, F. G. Njoroge, 1987, Carbohydrate research.

Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

X. Tong, R. Ralston, B. Feld, 2010, Antimicrobial Agents and Chemotherapy.

Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.

W. R. Bishop, F. G. Njoroge, C. Strickland, 2003, Bioorganic & medicinal chemistry.

Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Journal of medicinal chemistry.

Discovery of SCH 900188: A Potent Hepatitis C Virus NS5B Polymerase Inhibitor Prodrug As a Development Candidate.

F. G. Njoroge, K. Cheng, S. Agrawal, 2014, ACS medicinal chemistry letters.

Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.

V. Madison, F. G. Njoroge, Melissa L. Blackman, 2010, Bioorganic & medicinal chemistry letters.

Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.

X. Tong, A. McPhail, A. Arasappan, 2010, Journal of medicinal chemistry.

Optimization of potency and pharmacokinetics of tricyclic indole derived inhibitors of HCV NS5B polymerase. Identification of ester prodrugs with improved oral pharmacokinetics.

J. Duca, F. G. Njoroge, S. Agrawal, 2014, Bioorganic & medicinal chemistry.

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

S. Lemon, X. Tong, N. Bourne, 2006, Journal of Biological Chemistry.

6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.

Z. Gu, H. Ren, A. Nomeir, 2015, Bioorganic & medicinal chemistry letters.

Synthesis of new 4,5-dihydrofuranoindoles and their evaluation as HCV NS5B polymerase inhibitors.

José Duca, J. Duca, F. G. Njoroge, 2012, Organic letters.

Syntheses of 4- and 6-substituted thiazolo[4,5-c]pyridines

M. Senior, M. Maccoss, N. Bansal, 2010 .

Friedel-Crafts acylation with N-(trifluoroacetyl)-.alpha.-amino acid chlorides. Application to the preparation of .beta.-arylalkylamines and 3-substituted 1,2,3,4-tetrahydroisoquinolines

F. G. Njoroge, M. Payne, J. Nordlander, 1984 .

P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.

V. Madison, A. Arasappan, F. G. Njoroge, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.

V. Madison, F. G. Njoroge, A. Prongay, 2005, Bioorganic & medicinal chemistry letters.

Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.

F. G. Njoroge, N. Shih, J. Piwinski, 2008, Accounts of chemical research.

Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.

N. Yao, V. Madison, F. G. Njoroge, 2006, Journal of medicinal chemistry.

The double addition reaction of alkoxymethyl nucleophiles to esters to generate novel polyoxygenated species

Vishal A. Verma, A. Arasappan, F. G. Njoroge, 2010 .

Application of ruthenium induced cyclization for construction of strained biaryl ether macrocyclic compounds

F. G. Njoroge, V. Girijavallabhan, S. Venkatraman, 2002 .

Discovery of an irreversible HCV NS5B polymerase inhibitor.

J. Gesell, J. Duca, F. G. Njoroge, 2013, Bioorganic & medicinal chemistry letters.

The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.

Zhuyan Guo, Frank Bennett, X. Tong, 2010, Bioorganic & medicinal chemistry letters.

Synthesis of sterically hindered 3,5,5-trimethyl 2,6-dioxo tetrahydro pyrimidine as HCV protease inhibitors

R. Doll, F. G. Njoroge, N. Shih, 2010 .

Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.

R. Doll, Zhuyan Guo, A. Arasappan, 2010, Bioorganic & medicinal chemistry.

Practical and efficient method for amino acid derivatives containing β-quaternary center: application toward synthesis of hepatitis C virus NS3 serine protease inhibitors

A. Arasappan, F. G. Njoroge, T. Meng, 2007 .

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

Weiying Yang, Zhuyan Guo, Andrea Hart, 2006, Journal of medicinal chemistry.

Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.

F. G. Njoroge, A. Prongay, J. Pichardo, 2006, Bioorganic & medicinal chemistry letters.

An efficient synthesis of 3,4-dihydropyridone via a tandem olefin isomerization–ring-closing metathesis reaction

F. G. Njoroge, Chong Si, K. Fales, 2014 .

Novel synthesis of sterically hindered N-substituted lactams from imides

F. G. Njoroge, T. Chan, N. Shih, 2006 .

Highly Regioselective Nitration Reactions Provide a Versatile Method of Functionalizing Benzocycloheptapyridine Tricyclic Ring Systems: Application toward Preparation of Nanomolar Inhibitors of Farnesyl Protein Transferase.

R. Doll, S. Remiszewski, F. G. Njoroge, 1998, The Journal of organic chemistry.

N-(Trifluoroacetyl)-.alpha.-amino acid chlorides as chiral reagents for Friedel-Crafts synthesis

F. G. Njoroge, M. Payne, J. Nordlander, 1985 .

Macrocyclic inhibitors of HCV NS3 protease

F. G. Njoroge, F George Njoroge, Srikanth Venkatraman, 2009, Expert opinion on therapeutic patents.

Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.

P. Weber, R. Doll, W. Windsor, 1999, Journal of medicinal chemistry.

Enzymatic kinetic resolution of piperidine atropisomers: synthesis of a key intermediate of the farnesyl protein transferase inhibitor, SCH66336.

R. Jain, D. Dodds, F. G. Njoroge, 2000, The Journal of organic chemistry.

Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.

Ramesh Kakarla, Guangming Chen, Song Huang, 2014, Journal of medicinal chemistry.

A Short Enantiospecific Synthesis of 2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN).

F. G. Njoroge, M. Payne, J. Nordlander, 1986 .

A short enantiospecific synthesis of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN)

F. G. Njoroge, M. Payne, J. Nordlander, 1985 .

A review of HCV protease inhibitors.

F. G. Njoroge, Kevin X. Chen, 2009, Current opinion in investigational drugs.

Discovery of Boceprevir and Narlaprevir: The First and Second Generation of HCV NS3 Protease Inhibitors

F. G. Njoroge, Kevin X. Chen, F. Njoroge, 2012 .

Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.

W. R. Bishop, A. Nomeir, F. G. Njoroge, 2006, Bioorganic & medicinal chemistry letters.

Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.

W. R. Bishop, R. Doll, A. Nomeir, 1998, Journal of medicinal chemistry.

Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.

N. Yao, A. Arasappan, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

A short synthesis of (S)-(+)-tylophorine

F. G. Njoroge, J. Nordlander, F. Njoroge, 1987 .

Novel methods to functionalize thiazolo[4,5-c]pyridines

M. Maccoss, A. Arasappan, F. G. Njoroge, 2010 .

Intervention of Hepatitis C Replication through NS3‐4A, the Protease Inhibitor Boceprevir

F. G. Njoroge, S. Venkatraman, F. Njoroge, 2011 .

3-(D-Erythro-Trihydroxypropyl)-1-Neopentyl Pyrrole-2-Carboxaldehyde. A Novel Nonenzymatic Browning Product of Glucose

V. Monnier, F. G. Njoroge, A. A. Fernandes, 1987 .

A farnesyl transferase inhibitor suppresses TPA‐mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse

W. R. Bishop, R. Tennant, J. Haseman, 2000, Molecular carcinogenesis.

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.

W. R. Bishop, P. Kirschmeier, L. Wang, 1998, Journal of medicinal chemistry.

Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.

W. R. Bishop, P. Kirschmeier, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Novel inhibitors of the hepatitis C virus NS3 proteinase.

B. Dasmahapatra, A. Arasappan, F. G. Njoroge, 2005, Bioorganic & medicinal chemistry letters.

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Walter A. Korfmacher, W. R. Bishop, J. Catino, 1998, Cancer research.

Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.

W. R. Bishop, J. Catino, M. Malkowski, 1997, Journal of medicinal chemistry.

Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.

W. R. Bishop, N. Carruthers, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

Bridgehead Modification of Trihalocycloheptabenzopyridine Lead to a Potent Farnesyl Protein Transferase Inhibitor with Improved Oral Metabolic Stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2005 .

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.

Zhuyan Guo, Frank Bennett, Rong-Sheng Yang, 2007, Journal of medicinal chemistry.

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.

X. Tong, P. Qiu, Zhuyan Guo, 2006, Biochemistry.

Computational Study of the Effects of Mutations A156T, D168V, and D168Q on the Binding of HCV Protease Inhibitors.

X. Tong, T. Fischmann, Zhuyan Guo, 2006, Journal of chemical theory and computation.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Weiying Yang, Frank Bennett, Jesse Wong, 2010, ACS medicinal chemistry letters.

Mechanism of formation of the putative advanced glycosylation end product and protein cross-link 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole.

V. Monnier, F. G. Njoroge, A. A. Fernandes, 1988, The Journal of biological chemistry.

Novel Inhibitors of Hepatitis C NS3—NS4A Serine Protease Derived from 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic Acid.

F. G. Njoroge, A. Prongay, J. Pichardo, 2006 .

Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.

S. Tamura, S. Kemp, M. Lim-Wilby, 2006, Journal of medicinal chemistry.

Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models

P. Iversen, Y. Qian, Matthew R. Lee, 2018, Scientific Reports.

Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.

N. Yao, V. Madison, F. G. Njoroge, 2005, Journal of medicinal chemistry.

Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.

Weiying Yang, Frank Bennett, X. Tong, 2009, Journal of medicinal chemistry.

Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase.

J. Duca, F. G. Njoroge, S. Agrawal, 2013, Bioorganic & medicinal chemistry.

Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.

Robert Chase, Sony Agrawal, X. Tong, 2008, Biochemical pharmacology.

2′-Modified Guanosine Analogs for the Treatment of HCV

Q. Dang, A. Stamford, Vishal A. Verma, 2016, Nucleosides, Nucleotides & Nucleic Acids.

Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Bioorganic & Medicinal Chemistry.

Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.

S. Tamura, N. Yao, B. Malcolm, 2005, Bioorganic & medicinal chemistry letters.

Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.

Zhuyan Guo, Frank Bennett, Sumei Ruan, 2009, Journal of medicinal chemistry.

Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.

Frank Bennett, X. Tong, A. Arasappan, 2009, Journal of medicinal chemistry.

Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.

F. G. Njoroge, S. Agrawal, S. Ruan, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of geminal substitutions at the C5' carbosugar position of pyrimidine-derived HCV inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Interferon in Replicon Cells Enhances the Antiviral Activity of Alpha Suppresses Polyprotein Maturation and of Hepatitis C Virus NS 3 Protease , SCH 503034 , a Mechanism-Based Inhibitor

F. Gheyas, X. Tong, C. Jiang, 2005 .

Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.

V. Madison, A. Arasappan, F. G. Njoroge, 2005, Bioorganic & medicinal chemistry letters.

Macrocyclic inhibitors of HCV NS3-4A protease: design and structure activity relationship.

F. G. Njoroge, S. Venkatraman, 2007, Current Topics in Medicinal Chemistry.